OSLO, Norway, April 3, 2020 /PRNewswire/ -- Targovax
ASA (OSE: TRVX) announces that its nomination committee has
nominated Mr. Damian Marron for
election as Chairman of the Board at the company's Annual General
Meeting.
Mr. Damian Marron is an
experienced non-executive director, corporate advisor and life
science executive with a successful track record of value creation
through public and venture capital financing, portfolio planning,
M&A, licensing agreements as well as R&D collaborations,
both as an executive and in advisory roles. He has notably
specialized in immuno-oncology, cell therapy and orphan diseases.
Mr. Marron is currently Non-Executive Director at Bone
Therapeutics a clinical stage, regenerative medicine company
listed on Euronext and Resolys Bio, a private, late pre-clinical US
startup. He is also Head of Biopharma with Treehill Partners, a
global pure-play healthcare advisory firm. Mr. Marron has formerly
been Chair of the Board of PepGen Ltd and the CEO at Agalimmune
Ltd, TxCell SA, Cytheris SA, and Trophos SA.
Chairman of the Nomination Committee, Mr. Ludvik Sandnes says: "We are very pleased to
propose Mr. Damian Marron as new
Chairman of the Board. At this stage of the development of
Targovax, it is important to propose a proven Chairman with
extensive industry experience to achieve our commercial and
scientific goals. He has a very strong track record of value
creation through public and VC financing, M&A, strategic and
portfolio planning and company development. His wide network of
contacts globally from big pharma through to biotech companies and
with investors, banks and analysts will prove invaluable. This will
enable him to bring considerable experience and solutions to
Targovax as we continue to develop our clinical pipeline of
oncolytic viruses to target hard-to-treat solid tumors for
patients."
Mr. Marron is proposed to replace Mr. Patrick Vink, MD, who has informed the
Nomination Committee that he will not stand for re-election at the
upcoming AGM due to increased workload, responsibilities and
competing priorities. Targovax expresses the company's gratitude
for the excellent work Mr. Vink has done as Chairman of the Board
over the past three years.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications
(Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa-announces-proposed-new-chairman-of-the-board,c3079411